|
pubmed:abstractText |
Three groups of 40 patients each entered this prospective randomized trial. Patients of group A received 2 ml/kg body weight CMV-Polyglobulin, patients of group B 15 g Intraglobin and patients of group C, serving as controls, received no specific anti-CMV prophylaxis. All patients were given the same sequential immunosuppressive therapy. Patient survival and graft function did not show any significant differences at 2 years follow up. The incidence of fever, CMV infections, dialysis and steroid bolus therapy were lower in group A, but without statistical significance. Patients receiving a graft from a CMV-AK-positive donor were at high risk of developing an infection or reactivation of CMV. A study examining this subgroup seems appropriate.
|
